The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

MLA

Francis, K. E., et al. “The Impact of Olaparib Dose Reduction and Treatment Interruption on Treatment Outcome in the SOLO2/ENGOT-Ov21 Platinum-Sensitive Recurrent Ovarian Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 33, no. 6, June 2022, pp. 593–601. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.02.222.

APA

Francis, K. E., Kim, S. I., Friedlander, M., Gebski, V., Ray-Coquard, I., Clamp, A., Penson, R. T., Oza, A., Perri, T., Huzarski, T., Martin-Lorente, C., Cecere, S. C., Colombo, N., Ataseven, B., Fujiwara, K., Sonke, G., Vergote, I., Pujade-Lauraine, E., Kim, J.-W., & Lee, C. K. (2022). The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 33(6), 593–601. https://doi.org/10.1016/j.annonc.2022.02.222

Chicago

Francis, K E, S I Kim, M Friedlander, V Gebski, I Ray-Coquard, A Clamp, R T Penson, et al. 2022. “The Impact of Olaparib Dose Reduction and Treatment Interruption on Treatment Outcome in the SOLO2/ENGOT-Ov21 Platinum-Sensitive Recurrent Ovarian Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 33 (6): 593–601. doi:10.1016/j.annonc.2022.02.222.